Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Interstitial lung disease (ILD) is a risk factor for lung cancer. Patients with lung cancer associated with ILD (LC-ILD) often appear clinically. During the treatment of LC-ILD, there is a risk of causing acute exacerbation or even death in the treatment of lung cancer. At the same time, combining ILD has become the exclusion criteria for prospective clinical trials of most lung cancers. Therefore, when lung cancer is combined with ILD, it often becomes a difficult point for the treatment of lung cancer. Because LC-ILD patients have a certain proportion in the clinic, it is necessary to explore the best treatment options. Here we review the results of existing clinical studies for reference.


Yanning Wang, Yujie Zhou, Liyun Miao. A Review of Drug Therapy of Lung Cancer with Interstitial Lung Disease]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2020 Apr 20;23(4):286-293

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 32316717

View Full Text